EUVIMEDEUVIMED entdecken
Crossref

Oncologic Outcomes by Pathogenic BRCA Mutation Status in Young Luminal Breast Cancer: A Propensity-Matched Cohort

Woong Ki Park iD, Seok Jin Nam, Seok Won Kim, Jeong Eon Lee iD, Jonghan Yu iD, Se Kyung Lee iD, Jai Min Ryu iD, Jin Seok Ahn iD, Yeon Hee Park iD, Ji-Yeon Kim iD, Byung Joo Chae iD

JCO Precision Oncology · 2026-01 · 10 (1)

DOI: 10.1200/po-25-00445 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2026-01. Verfasst von Woong Ki Park und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. Hauptthemen laut MEDLINE: Breast Neoplasms, Mutation, BRCA2 Protein, BRCA1 Protein. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Young patients with estrogen receptor (ER)–positive, human epidermal growth factor receptor 2 (HER2)–negative tumors often exhibit poor outcomes. This study evaluated whether BRCA mutation contributes to prognosis by comparing oncologic outcomes according to BRCA status. MATERIALS AND METHODS We conducted a retrospective study of a prospective institutional cohort. Among 1,025 patients 40 years and younger with ER-positive, HER2-negative breast cancer who underwent BRCA1/2 testing, 967 patients were included (excluding low ER expression). Ninety-eight patients (10.1%) were BRCA mutation carriers. Propensity score matching (1:4) and multivariate Cox regression were performed using covariates differing between groups. RESULTS BRCA mutation carriers showed more aggressive features. They had worse distant metastasis-free survival (DMFS) compared with noncarriers (hazard ratio [HR], 2.40, P < .001), with a greater risk in late DMFS beyond 5 years (HR, 3.50, P < .001). These findings persisted after adjustment (DMFS HR, 1.76, P = .038, late DMFS HR, 2.84, P = .009). Overall survival was not significantly different. Bone was the most common first site of metastasis in BRCA carriers, whereas noncarriers more frequently showed metastasis to multiple sites. In exploratory subgroup analysis, luminal A–like BRCA carriers consistently showed the poorest survival among the four subgroups. CONCLUSION In luminal-type YBC excluding low ER expression, BRCA carriers demonstrated more aggressive features and significantly worse distant metastasis outcomes. These findings support the need for long-term surveillance and consideration of tailored treatment strategies, including PARP inhibitors, in this high-risk population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsMutationBRCA2 ProteinBRCA1 ProteinHumansFemaleRetrospective StudiesAdultPropensity ScorePrognosisCohort Studies

Substanzen

BRCA2 ProteinBRCA1 ProteinBRCA2 protein, humanBRCA1 protein, human

Autor:innen und Institutionen

  • Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Department of Health Sciences and Technology, Samsung Advanced Institute for Health Science & Technology, Sungkyunkwan University, Seoul, South Korea.

ORCID-Profile: Woong Ki Park, Jeong Eon Lee, Jonghan Yu, Se Kyung Lee, Jai Min Ryu, Jin Seok Ahn, Yeon Hee Park, Ji-Yeon Kim, Byung Joo Chae

Zitieren

APA

Park, W. K., Nam, S. J., Kim, S. W., Lee, J. E., Yu, J., Lee, S. K., Ryu, J. M., Ahn, J. S., Park, Y. H., Kim, J. Y., & Chae, B. J. (2026). Oncologic Outcomes by Pathogenic BRCA Mutation Status in Young Luminal Breast Cancer: A Propensity-Matched Cohort. JCO Precision Oncology, 10(1). https://doi.org/10.1200/po-25-00445

Vancouver

Park WK, Nam SJ, Kim SW, Lee JE, Yu J, Lee SK, et al. Oncologic Outcomes by Pathogenic BRCA Mutation Status in Young Luminal Breast Cancer: A Propensity-Matched Cohort. JCO Precision Oncology. 2026;10(1). doi:10.1200/po-25-00445

BibTeX
@article{Park2026,
  author = {Park, Woong Ki and Nam, Seok Jin and Kim, Seok Won and Lee, Jeong Eon and Yu, Jonghan and Lee, Se Kyung and Ryu, Jai Min and Ahn, Jin Seok and Park, Yeon Hee and Kim, Ji-Yeon and Chae, Byung Joo},
  title = {Oncologic Outcomes by Pathogenic BRCA Mutation Status in Young Luminal Breast Cancer: A Propensity-Matched Cohort},
  journal = {JCO Precision Oncology},
  year = {2026},
  volume = {10},
  number = {1},
  doi = {10.1200/po-25-00445}
}
Kostenlos starten →